JPMorgan Chase & Co. Boosts Stock Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

JPMorgan Chase & Co. raised its holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 40.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 190,385 shares of the company's stock after acquiring an additional 54,482 shares during the quarter. JPMorgan Chase & Co. owned about 0.14% of Centessa Pharmaceuticals worth $3,189,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its position in shares of Centessa Pharmaceuticals by 39.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock valued at $317,000 after buying an additional 5,316 shares in the last quarter. GAMMA Investing LLC grew its stake in Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock valued at $64,000 after acquiring an additional 865 shares during the period. Lord Abbett & CO. LLC bought a new stake in shares of Centessa Pharmaceuticals in the third quarter worth about $4,305,000. Franklin Resources Inc. raised its position in shares of Centessa Pharmaceuticals by 99.1% during the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company's stock worth $38,360,000 after purchasing an additional 1,145,823 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Centessa Pharmaceuticals by 68.7% during the 3rd quarter. Geode Capital Management LLC now owns 56,597 shares of the company's stock valued at $905,000 after purchasing an additional 23,058 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CNTA. Guggenheim reaffirmed a "buy" rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Morgan Stanley reiterated an "overweight" rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. TD Cowen initiated coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating on the stock. Finally, Piper Sandler assumed coverage on shares of Centessa Pharmaceuticals in a research note on Monday, March 31st. They set an "overweight" rating and a $38.00 price target for the company. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $27.71.

Centessa Pharmaceuticals Trading Up 1.3 %

CNTA traded up $0.18 during midday trading on Friday, hitting $13.79. 480,936 shares of the company were exchanged, compared to its average volume of 605,883. The firm has a market capitalization of $1.84 billion, a P/E ratio of -9.01 and a beta of 1.53. The firm's 50 day moving average price is $14.42 and its 200-day moving average price is $15.87. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.04. As a group, equities analysts forecast that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 11,742 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $13.61, for a total transaction of $159,808.62. Following the transaction, the insider now owns 122,279 shares of the company's stock, valued at $1,664,217.19. This trade represents a 8.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Karen M. Anderson sold 6,471 shares of Centessa Pharmaceuticals stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $16.86, for a total value of $109,101.06. Following the sale, the insider now owns 54,322 shares in the company, valued at $915,868.92. This trade represents a 10.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 225,566 shares of company stock valued at $3,690,409 over the last three months. Corporate insiders own 11.59% of the company's stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.